AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9583342 — intervention group
Group type: COMPARATOR
Intervention: Minimal-contact control group
Number of subjects: 523
Study 10404421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour tea (Hibiscus sabdariffa)
Number of subjects: 54
Study 10404421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 1854051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) at doses of 0.012, 0.025, and 0.05 mg.kg‐1.min‐1
Number of subjects: 20
Study 1854051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6344732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subcuticular suture and sterile Micropore tape
Number of subjects: 169
Study 6344732 — intervention group
Group type: COMPARATOR
Intervention: Conventional interrupted sutures
Number of subjects: 169
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubist model
Number of subjects: 156
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 156
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Artificial Neural Network (avNNET) model
Number of subjects: 156
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (nnet) model
Number of subjects: 156
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Least Squares Regression (PLSR) model
Number of subjects: 156
Study 30876552 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus model
Number of subjects: 156
Study 29870591 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir 400 mg with montelukast 10 mg
Number of subjects: 48
Study 29870591 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenamevir 400 mg with bupropion 150 mg
Number of subjects: 48
Study 26045008 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential subcuticular wound approximation (CSWA)
Number of subjects: 121
Study 26045008 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure
Number of subjects: 121
Study 23720840 — intervention group
Group type: EXPERIMENTAL
Intervention: CF patients with carbohydrate metabolic disturbances (CMD)
Number of subjects: 350
Study 23720840 — intervention group
Group type: COMPARATOR
Intervention: CF patients without CMD
Number of subjects: 350
Study 23720840 — intervention group
Group type: EXPERIMENTAL
Intervention: CF patients with impaired glucose tolerance (IGT)
Number of subjects: 350
Study 23720840 — intervention group
Group type: EXPERIMENTAL
Intervention: CF patients with CF-dependent diabetes mellitus (CFDDM)
Number of subjects: 350
Study 21194357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (DPPIV inhibitor)
Number of subjects: 6
Study 21194357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 18651257 — intervention group
Group type: EXPERIMENTAL
Intervention: MR arthrography with Gd-DTPA2- injection and comprehensive imaging (static and dynamic)
Number of subjects: 23
Study 18651257 — intervention group
Group type: EXPERIMENTAL
Intervention: Static MR imaging
Number of subjects: 23
Study 18651257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic motion MR imaging
Number of subjects: 23
Study 17050788 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg once daily for 7 days (n = 8)
Number of subjects: 24
Study 17050788 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily for 6 days with a single dose on day 7 (n = 8)
Number of subjects: 24
Study 17050788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 24
Study 15727187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex nutritional intervention group (100 g coarse food grain every day and nutrition education)
Number of subjects: 260
Study 15727187 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplex nutritional intervention group (only nutrition education)
Number of subjects: 260
Study 15727187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study 11004017 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 min)
Number of subjects: 18
Study 11004017 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microg/kg bolus)
Number of subjects: 18
Study 11004017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-arginine and GHRP-2 (AG)
Number of subjects: 18
Study 11004017 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 18
Study 9006223 — intervention group
Group type: EXPERIMENTAL
Intervention: New visual agenda-setting technology and other visual aids applied using negotiation and motivational interviewing
Number of subjects: 200
Study 1346342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 63
Study 1346342 — intervention group
Group type: COMPARATOR
Intervention: Control (triple therapy without amiodarone)
Number of subjects: 63
Study 6088192 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (41% carbohydrates, 41% fat)
Number of subjects: 6
Study 6088192 — intervention group
Group type: COMPARATOR
Intervention: Diet B (60% carbohydrates, 20% fat)
Number of subjects: 6
Study 6088192 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal with 12 g olive oil
Number of subjects: 6
Study 6088192 — intervention group
Group type: COMPARATOR
Intervention: Standard meal with 36 g olive oil
Number of subjects: 6
Study 29101120 — intervention group
Group type: EXPERIMENTAL
Intervention: VOICES-SF questionnaire
Number of subjects: 0
Study 29101120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study methods
Number of subjects: 0
Study 29101120 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective mortality follow-back method
Number of subjects: 0
Study 29427024 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg, once-daily)
Number of subjects: 16
Study 29427024 — intervention group
Group type: COMPARATOR
Intervention: voglibose (0.9 mg, thrice-daily)
Number of subjects: 16
Study 29427024 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 16
Study 27009045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter using insights from behavioural science
Number of subjects: 3511
Study 27009045 — intervention group
Group type: COMPARATOR
Intervention: Standard national invitation template letter
Number of subjects: 3511
Study 25042737 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐LMR ≥ 1.0 in the training set
Number of subjects: 379
Study 25042737 — intervention group
Group type: COMPARATOR
Intervention: A‐LMR < 1.0 in the training set
Number of subjects: 379
Study 25042737 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐LMR ≥ 1 in the validation set
Number of subjects: 379
Study 25042737 — intervention group
Group type: COMPARATOR
Intervention: A‐LMR < 1 in the validation set
Number of subjects: 379
Study 22753863 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×60 min a week of supervised high‐intensity strength training for 20 weeks
Number of subjects: 447
Study 22753863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×20 min a week of supervised high‐intensity strength training for 20 weeks
Number of subjects: 447
Study 22753863 — intervention group
Group type: EXPERIMENTAL
Intervention: 9×7 min a week of supervised high‐intensity strength training for 20 weeks
Number of subjects: 447
Study 22753863 — intervention group
Group type: COMPARATOR
Intervention: Reference group without training (REF)
Number of subjects: 447
Study 20965305 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex PD group
Number of subjects: 134
Study 20965305 — intervention group
Group type: COMPARATOR
Intervention: No PD, personality difficulty, simple PD groups
Number of subjects: 134
Study 16784903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (ML1)
Number of subjects: 22
Study 16784903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16332235 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + NBM
Number of subjects: 24
Study 16332235 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + beta‐TCP
Number of subjects: 24
Study 12149667 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 12
Study 12149667 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/day)
Number of subjects: 12
Study 12149667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Trandolapril 0.5 mg/day + Irbesartan 150 mg/day)
Number of subjects: 12
Study 12149667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9539500 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (platelet glycoprotein IIb/IIIa inhibitor)
Number of subjects: 0
Study 9539500 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group not explicitly mentioned)
Number of subjects: 0
Study 15490780 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (Tetric)
Number of subjects: 12
Study 15490780 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer cement (Ketac Fil)
Number of subjects: 12
Study 15490780 — intervention group
Group type: EXPERIMENTAL
Intervention: Final restorations (ceramic inlays - Empress)
Number of subjects: 12
Study 2618843 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-placebo (information based) smoking prevention program
Number of subjects: 14
Study 2618843 — intervention group
Group type: COMPARATOR
Intervention: Experimental social influences program
Number of subjects: 14
Study 337478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of glycerol (25 g twice daily for 6 days)
Number of subjects: 26
Study 337478 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 26
Study 30779861 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity Fracture Liaison Service (FLS) Case-Manager intervention
Number of subjects: 361
Study 30779861 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity FLS (Active Control)
Number of subjects: 361
Study 30779861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361
Study 28932387 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite provocations
Number of subjects: 86
Study 28932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen provocations
Number of subjects: 86
Study 28932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen provocations
Number of subjects: 86
Study 28932387 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen or pollen concentrations
Number of subjects: 86
Study 28932387 — intervention group
Group type: COMPARATOR
Intervention: Baseline PNIF
Number of subjects: 86
Study 26115386 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity
Number of subjects: 1635
Study 26115386 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 1635
Study 23499068 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof SA60AT (1‐piece IOL group)
Number of subjects: 80
Study 23499068 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40e (3‐piece IOL group)
Number of subjects: 80
Study 21684508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg
Number of subjects: 100
Study 21684508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 100
Study 21684508 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 50 mg or 100 mg
Number of subjects: 100
Study 19015284 — intervention group
Group type: EXPERIMENTAL
Intervention: Written descriptions plus photographs of patients with SSc
Number of subjects: 213
Study 19015284 — intervention group
Group type: COMPARATOR
Intervention: Written descriptions only
Number of subjects: 213
Study 16953009 — intervention group
Group type: COMPARATOR
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 1236
Study 16953009 — intervention group
Group type: COMPARATOR
Intervention: SFP 10-14 + Life Skills Training (LST)
Number of subjects: 1236
Study 16953009 — intervention group
Group type: COMPARATOR
Intervention: LST alone
Number of subjects: 1236
Study 15235301 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise training
Number of subjects: 32
Study 15235301 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 32
Study 11334905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% saline infusion on day 3 or 4 after hCG administration in IVF patients
Number of subjects: 13
Study 11334905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% saline infusion test on day 10 after hCG administration
Number of subjects: 13
Study 11334905 — intervention group
Group type: COMPARATOR
Intervention: 5% saline infusion in controls (normal menstrual cycles)
Number of subjects: 13
Study 9397100 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for predicting vaginal birth after cesarean delivery
Number of subjects: 5022
Study 9397100 — intervention group
Group type: COMPARATOR
Intervention: Control group (score testing)
Number of subjects: 5022
Study 8188494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with employee steering committees selecting health education and environmental change activities.
Number of subjects: 26
Study 8188494 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 26
Study 3668801 — intervention group
Group type: EXPERIMENTAL
Intervention: oral solution
Number of subjects: 12
Study 3668801 — intervention group
Group type: COMPARATOR
Intervention: intravenous infusion
Number of subjects: 12
Study 3668801 — intervention group
Group type: COMPARATOR
Intervention: oral capsules
Number of subjects: 12
Study 29306880 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free law compliance measures (systematic objective observations)
Number of subjects: 222
Study 29306880 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and opinions regarding the smoke-free law
Number of subjects: 222
Study 29306880 — intervention group
Group type: EXPERIMENTAL
Intervention: Air quality testing (PM 2.5 levels)
Number of subjects: 222
Study 27647671 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label lithium
Number of subjects: 42
Study 27647671 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42
Study 27647671 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 42
Study 25544247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system
Number of subjects: 38
Study 25544247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 15 μg sublingual tablet (SL) administered using the SSTS system (40 consecutive doses)
Number of subjects: 38
Study 25544247 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of sufentanil
Number of subjects: 38
Study 25544247 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil buccal (BU) administration
Number of subjects: 38
Study 25544247 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil oral (PO) administration
Number of subjects: 38
Study 25544247 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil sublingual (SL) administration
Number of subjects: 38
Study 22855038 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony capsule (TGPC), 600 mg per time, three times daily for three months
Number of subjects: 86
Study 22855038 — intervention group
Group type: COMPARATOR
Intervention: Compound glycyrrhizin tablet, 50 mg per time, three times daily for three months
Number of subjects: 86
Study 20798432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 20798432 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 20798432 — intervention group
Group type: COMPARATOR
Intervention: Stopping antiplatelet agents
Number of subjects: 0
Study 20798432 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach of stopping medications up to two weeks before surgery
Number of subjects: 0
Study 18718769 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse foam sclerotherapy with sapheno-femoral junction (SFJ) ligation
Number of subjects: 90
Study 18718769 — intervention group
Group type: COMPARATOR
Intervention: Standard stripping with SFJ ligation
Number of subjects: 90
Study 18718769 — intervention group
Group type: COMPARATOR
Intervention: Invagination stripping with SFJ ligation
Number of subjects: 90
Study 16298920 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency of 500 ms
Number of subjects: 5
Study 16298920 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher latency (greater than 300 ms)
Number of subjects: 5
Study 16298920 — intervention group
Group type: EXPERIMENTAL
Intervention: Different latencies
Number of subjects: 5
Study 12463311 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester margarine
Number of subjects: 81
Study 12463311 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 81
Study 10514159 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low intensity coumarin (international normalised ratio 1.1-1.6)
Number of subjects: 729
Study 10514159 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intensity coumarin (international normalised ratio 2.5-3.5)
Number of subjects: 729
Study 10514159 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anticoagulation
Number of subjects: 729
Study 10514159 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (150 mg/day)
Number of subjects: 729
Study 8719595 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNOR staining
Number of subjects: 73
Study 8719595 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA cytofluorometry
Number of subjects: 73
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg or higher
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 11.25 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 15 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.5 mg and 7.5 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone up to 11.25 mg
Number of subjects: 60
Study 2201721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone higher doses when well tolerated
Number of subjects: 60
Study 2201721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 84947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 0
Study 30912259 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 909
Study 30912259 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 909
Study 29020150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1.0 g, intravenously, once daily for 10 days)
Number of subjects: 301
Study 29020150 — intervention group
Group type: COMPARATOR
Intervention: Benzathine Penicillin G (2.4 million units, intramuscularly, once weekly for 2 weeks)
Number of subjects: 301
Study 29020150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 301
Study 29020150 — intervention group
Group type: COMPARATOR
Intervention: Benzathine Penicillin G
Number of subjects: 301
Study 29020150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone or BPG
Number of subjects: 301
Study 25695770 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 19)
Number of subjects: 53
Study 25695770 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (n = 14)
Number of subjects: 53
Study 25695770 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 53
Study 22904115 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise program (experimental group)
Number of subjects: 20
Study 22904115 — intervention group
Group type: COMPARATOR
Intervention: Relaxation only (control group)
Number of subjects: 20
Study 19095403 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing
Number of subjects: 139
Study 19095403 — intervention group
Group type: COMPARATOR
Intervention: Clinical algorithm (control)
Number of subjects: 139
Study 19585767 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat medic training
Number of subjects: 3792
Study 16990966 — intervention group
Group type: EXPERIMENTAL
Intervention: VBM laryngeal tube (LT)
Number of subjects: 40
Study 16990966 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 40
Study 15208051 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg weekly
Number of subjects: 40
Study 15208051 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 10 mg planned postcoitally
Number of subjects: 40
Study 11122028 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time teledermatology
Number of subjects: 96
Study 11122028 — intervention group
Group type: COMPARATOR
Intervention: Store-and-forward teledermatology
Number of subjects: 96
Study 9272610 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies that lower glucose levels
Number of subjects: 0
Study 9272610 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8441426 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ft3 (0.57 m3) of outdoor air per minute per person
Number of subjects: 1546
Study 8441426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ft3 (1.4 m3) of outdoor air per minute per person
Number of subjects: 1546
Study 3533776 — intervention group
Group type: EXPERIMENTAL
Intervention: Milch's technique
Number of subjects: 111
Study 3533776 — intervention group
Group type: COMPARATOR
Intervention: Kocher's technique
Number of subjects: 111
Study 30947737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices received £1500, a support manual, and four meetings to develop local solutions.
Number of subjects: 34